Inhibiting the IGF-1 receptor tyrosine kinase with the cyclolignan PPP: an in vitro and in vivo study in the 5T33MM mouse model
Open accessThe DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
Insulin-like growth factor 1 (IGF-1) plays a pleiotropic role in multiple myeloma (MM), that is, in survival, proliferation, chemotaxis, and angiogenesis. Strategies targeting the IGF-1 receptor (IGF-1R) may therefore be important to develop efficient anti-MM agents. In this work we investigated the effect of an IGF-1R tyrosine kinase (IGF-1RTK) inhibitor (picropodophyllin or PPP) in the 5T33MM mouse model. In vitro data showed that PPP reduced IGF-1R autophosphorylation and downstream ERK activation, leading to inhibition of IGF-1–stimulated proliferation and vascular endothelial growth factor (VEGF) secretion of MM cells. In an in vivo study, PPP reduced the bone marrow tumor burden and serum paraprotein in 5T33MM mice by 77% and 90%, respectively, compared to vehicle-treated animals. Angiogenesis was assessed by quantifying the microvessel density on CD31-stained paraffin sections and this was reduced by 60% in the PPP-treated group. In a separate survival experiment, Kaplan-Meier analysis demonstrated a significant increase in survival in PPP-treated 5T33MM animals compared to the vehicle controls (28 versus 18 days). These data suggest that the IGF-1RTK inhibitor PPP possesses a marked antitumor activity and strongly points to the possibility of using IGF-1R inhibitors in the treatment of MM.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Lymphocyte Homing and Homeostasis
Butcher, E. C., & Picker, L. J. (1996) · Science · doi:10.1126/science.272.5258.60 · Cited by 2,846
Menu, E., Kooijman, R., Valckenborgh, E. V., Asosingh, K., Bakkus, M., Camp, B. V., & Vanderkerken, K. (2004) · British Journal of Cancer · doi:10.1038/sj.bjc.6601613 · Cited by 115
Self-citation
Cited by
Dysregulation of growth factor signaling in human hepatocellular carcinoma
Breuhahn, K., Longerich, T., & Schirmacher, P. (2006) · Oncogene · doi:10.1038/sj.onc.1209556 · Cited by 391
Modifying IGF1 activity: an approach to treat endocrine disorders, atherosclerosis and cancer
Clemmons, D. R. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2359 · Cited by 340
Microenvironment drug resistance in multiple myeloma: emerging new players
Di Marzo, L., Desantis, V., Solimando, A. G., Ruggieri, S., Annese, T., Nico, B., Fumarulo, R., Vacca, A., & Frassanito, M. A. (2016) · Oncotarget · doi:10.18632/oncotarget.10849 · Cited by 173
“[33, 34] demonstrated that picropodophyllin, a non-ATP-competitive IGF-1R tyrosine kinase inhibitor, inhibits tumor growth [33], MM-associated angiogenesis and bone disease [34] in 5T33MM-treated mice.”
BackgroundCorrea de Sampaio, P., Auslaender, D., Krubasik, D., Failla, A. V., Skepper, J. N., Murphy, G., & English, W. R. (2012) · PLoS ONE · doi:10.1371/journal.pone.0030753 · Cited by 127
IGF-1 suppresses Bim expression in multiple myeloma via epigenetic and posttranslational mechanisms
De Bruyne, E., Bos, T. J., Schuit, F., Van Valckenborgh, E., Menu, E., Thorrez, L., Atadja, P., Jernberg-Wiklund, H., & Vanderkerken, K. (2010) · Blood · doi:10.1182/blood-2009-07-232801 · Cited by 103
Self-citation
Metadata
- Authors
- Menu, E., Jernberg-Wiklund, H., Stromberg, T., De Raeve, H., Girnita, L., Larsson, O., Axelson, M., Asosingh, K., Nilsson, K., Van Camp, B., & Vanderkerken, K.
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2006-01-15
- Volume
- 107
- Issue
- 2
- Pages
- 655-660
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W2114321011
- Cited by
- 145
- References
- 2
- FWCI
- 9.64
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Inhibiting the IGF-1 receptor tyrosine kinase with the cyclolignan PPP: an in vitro and in vivo study in the 5T33MM mouse model. https://app.cochat.ai/papers/10.1182/blood-2005-01-0293
- The paper
- Menu, E., Jernberg-Wiklund, H., Stromberg, T., De Raeve, H., Girnita, L., Larsson, O., Axelson, M., Asosingh, K., Nilsson, K., Van Camp, B., & Vanderkerken, K. (2006). Inhibiting the IGF-1 receptor tyrosine kinase with the cyclolignan PPP: an in vitro and in vivo study in the 5T33MM mouse model. Blood. https://doi.org/10.1182/blood-2005-01-0293
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.